Ask Aeroz

Type the question you actually came here with.

DSCSA · deadlines and exemptions

DSCSA deadlines and exemption end dates.

DSCSA deadlines are the dates by which drug supply chain trading partners must meet the enhanced drug distribution security requirements: 27 November 2023 in the law, with FDA exemptions that ended in 2025 and a small dispenser exemption that runs to 27 November 2027.

The DSCSA enhanced drug distribution security requirements took effect on 27 November 2023 under section 582(g) of the FD&C Act. FDA then gave exemptions to eligible trading partners: manufacturers and repackagers until 27 May 2025, wholesale distributors until 27 August 2025, dispensers with 26 or more full-time employees until 27 November 2025, and small dispensers until 27 November 2027.

Section 582(g)27 Nov 202327 May 202527 Aug 202527 Nov 202527 Nov 2027
Key facts · reviewed

DSCSA deadlines, in three facts.

FD&C Act section 582(g) · enhanced requirements in effect 27 November 2023 · FDA exemptions of 9 October 2024 and 6 August 2026 · manufacturers, repackagers, wholesale distributors and dispensers.

What the rule requires

Every DSCSA date, in order.

27 November 2023: the date in the law

Section 582(g)(1) of the FD&C Act put interoperable, electronic tracing of product at the package level into effect on the date 10 years after 27 November 2013. From that date transaction information and statements are to be exchanged electronically, with the product identifier for each package.

27 November 2024: the stabilization period ends

FDA's August 2023 compliance policies gave a stabilization period to 27 November 2024. On 9 October 2024 FDA issued exemptions for trading partners that had started their systems and processes, including electronic data connections with their immediate trading partners, by that date. Those relying on them did not need to notify FDA.

2025: three exemptions end

Under the 9 October 2024 exemptions, eligible manufacturers and repackagers had until 27 May 2025, eligible wholesale distributors until 27 August 2025, and eligible dispensers with 26 or more full-time employees until 27 November 2025.

27 November 2027: small dispensers

FDA has exempted small dispensers, and where applicable their trading partners, from certain section 582 requirements until 27 November 2027. A dispenser is small if, as of 27 November 2026, the company that owns it has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians.

No exemption left? Ask FDA

A trading partner that does not qualify for an exemption and cannot meet the enhanced requirements can request a waiver, exception or exemption from FDA, through CDER NextGen for CDER-regulated products, and is expected to keep working toward the requirements until FDA decides.

The dates

The timeline, as it stands.

Only the small dispenser exemption is still running. For manufacturers, repackagers, wholesale distributors and dispensers with 26 or more full-time employees, the exemption periods have ended.

Enhanced requirements in effect27 Nov 2023
Manufacturers and repackagers exemption ended27 May 2025
Wholesale distributor exemption ended27 Aug 2025
Dispensers with 26 or more employees27 Nov 2025
Small dispenser exemption ends27 Nov 2027
What to do now

Three moves that de-risk the deadline.

01 · Step

Find your row in the table

Manufacturers, repackagers, wholesale distributors and dispensers with 26 or more full-time employees are past their exemption dates. Check whether your company is a small dispenser under FDA's 25-employee test.

02 · Step

Close the data gaps with each partner

List every immediate trading partner, the way you exchange transaction information with them and the errors you still see, and fix the connections that still fail.

03 · Step

Request a waiver if you cannot comply

If you cannot meet a requirement and no exemption applies, send FDA a waiver or exemption request with the steps already taken, why more time is needed and the plan to finish.

How Aeroz fits

One record, ready for every date.

Because the tracing rules are federal, one system serves every state you operate in. Aeroz ties each unit's physical identity to its transaction record, so the evidence a pharmacy produces is the same wherever it operates.

FAQ

DSCSA deadlines, answered.

What are the DSCSA deadlines?

The enhanced drug distribution security requirements took effect on 27 November 2023. FDA's stabilization period ended on 27 November 2024. Exemptions for eligible manufacturers and repackagers ended on 27 May 2025, for wholesale distributors on 27 August 2025 and for dispensers with 26 or more full-time employees on 27 November 2025. Small dispensers are exempt until 27 November 2027.

Is there a DSCSA extension?

Only for small dispensers. On 6 August 2026 FDA exempted small dispensers, and where applicable their trading partners, from certain section 582 requirements until 27 November 2027. The exemptions for other trading partners ended in 2025; a company that still cannot comply can request a waiver or exemption from FDA.

What is the DSCSA compliance deadline for wholesale distributors?

The requirements applied from 27 November 2023. Eligible wholesale distributors that had started their systems and data connections by 27 November 2024 were exempt from certain requirements until 27 August 2025.

When is the DSCSA deadline for manufacturers and repackagers?

The exemption for eligible manufacturers and repackagers covered products they introduced in a transaction into commerce from 27 November 2024 until 27 May 2025.

When does the DSCSA small dispenser exemption end?

On 27 November 2027. It covers pharmacies whose owning company had 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians as of 27 November 2026, and nobody has to file anything with FDA to use it.

Readiness audit

Know exactly where you stand, in 14 days.

A fixed-fee Aeroz audit maps your products against DSCSA deadlines, exemption end dates and the enhanced drug distribution security requirements and returns a written readiness assessment, a data-mapping review, and a scoped pilot plan with cost and timeline.

Fixed fee: Readiness Report $2,500, Readiness Audit $4,500 14-day written report No commitment to proceed